IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals a positive sentiment with strong revenue growth (25% YoY), improved gross margins, and reduced net loss. The company's strategic focus on breast cancer treatment and operational highlights indicate promising prospects. However, regulatory hurdles and competitive pressures present risks. Overall, the financial performance and strategic initiatives suggest a positive outlook for the stock price, likely to increase by 2% to 8% over the next two weeks.
Key Financial Performance
Revenue IceCure Medical reported revenue of $2.5 million for Q1 2026, representing a 25% increase year-over-year. The growth was attributed to increased adoption of their cryoablation technology in North America and Europe.
Gross Margin The gross margin improved to 65% in Q1 2026, up from 60% in the same period last year. This improvement was due to better operational efficiencies and cost management.
Operating Expenses Operating expenses rose to $1.8 million in Q1 2026, a 12% increase year-over-year. The rise was primarily due to higher investments in sales and marketing efforts to support the company's expansion.
Net Loss Net loss for Q1 2026 was $0.5 million, compared to $0.8 million in Q1 2025. The reduction in net loss was driven by higher revenues and improved gross margins.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Cryoablation Technology: Dr. Richard Fine highlighted the use of cryoablation in the treatment of early-stage breast cancer, emphasizing its growing adoption and the ICE3 data supporting its efficacy.
North America Sales Expansion: Shad Good, VP Sales North America, discussed increasing commercial momentum and growing engagement in the North American market.
Operational Highlights: The company reviewed financial results for Q1 2026, indicating operational progress and strategic focus on breast cancer treatment.
Strategic Focus on Breast Cancer: The company emphasized its strategic commitment to advancing cryoablation technology for early-stage breast cancer treatment, supported by clinical data and expert endorsements.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company faces regulatory challenges in expanding its cryoablation technology for breast cancer treatment, which could impact its strategic objectives and market expansion.
Market Conditions: There is uncertainty in market conditions that could affect the company's commercial momentum and engagement with healthcare providers.
Competitive Pressures: The company is experiencing competitive pressures in the medical technology field, which could impact its market share and financial performance.
Strategic Execution Risks: Challenges in executing strategic plans for expanding the use of cryoablation technology in new markets and applications could adversely affect the company's growth objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alliance Global
America Vendetti
Brian Kemp
Brookline Capital
CEO Director
Capital Markets
Director Shad
Division Brian
Division Instructions
Division Scott
Dolliver Brookline
EDT Eyal
Eyal CEO
Global Partners
Group LLC
Henry Alliance
IceCure momentum
Kemp Dolliver
LLC Research
Markets LLC
Partners Research
President Sales
Research Division
Sales North
Scott Henry
Shad Vice
Vice President
conference moment
momentum engagement
presentation IceCure
ICCM Transcript
IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call summary reveals a positive sentiment with strong revenue growth (25% YoY), improved gross margins, and reduced net loss. The company's strategic focus on breast cancer treatment and operational highlights indicate promising prospects. However, regulatory hurdles and competitive pressures present risks. Overall, the financial performance and strategic initiatives suggest a positive outlook for the stock price, likely to increase by 2% to 8% over the next two weeks.
IceCure Medical Ltd (ICCM) Q4 2025 Earnings Call Transcript
Positive3-17
The earnings call summary presents a positive outlook with record revenue, FDA marketing authorization, and strategic growth plans. The Q&A section highlights the company's efforts to improve reimbursement and expand into new markets, with some uncertainty in timelines. Despite challenges in scaling and market penetration, the strong financial performance and optimistic guidance suggest a positive stock price movement.
IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript
Unknown11-19
The company's financial performance shows declining revenue, gross profit, and margins, indicating challenges in maintaining profitability. Despite the optimism around FDA approval and market potential, the lack of a concrete timeline for regulatory approvals and the unclear management responses in the Q&A create uncertainty. The ongoing net losses and limited cash position add to financial strain. These factors, combined with supply chain and sales variability, suggest a negative market reaction, likely in the -2% to -8% range, especially given the lack of market cap information for a more precise prediction.
IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call reveals several concerns: declining revenue and gross margin, increased net loss, and dependency on FDA approval for U.S. market growth. The Q&A highlighted uncertainties around the post-market study budget and lack of specific sales projections for Europe and Japan. While there is interest in ProSense and potential reimbursement, the financial metrics and market adoption risks overshadow these positives, suggesting a negative sentiment.
ICCM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
